Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (September 2021)

37 slides from Sorrento Therapeutics's investor presentation, Sep 13, 2021

  1. Slide 1: Saving Life Medicine

    Saving Life TM Medicine September 20 21 NASDAQ : SRNE © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 1 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc . (the “Company” or “Sorrento”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this material, are or may be considered

  3. Slide 3: About the Company

    About the COMPANY • Funded and Operational in 2009 • NASDAQ: SRNE • HQ in San Diego, CA ~ 700 Employees worldwide ~100 Employees with PhDs & MDs ~5 00,000 SF Research and cGMP Manufacturing Facilities • 7 cGMP Manufacturing Sites (5 USA, 2 China) mAbs, Small Molecule, ADC, Plasmid DNA, Lymphatic Dru

  4. Slide 4: Transforming Innovative Platforms into Saving Life Medicines

    Transforming GMAB Ρ Innovative Platforms into Saving Life Ρ Medicines 4 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  5. Slide 5: Therapeutic Areas of Focus

    Cancer © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 5 Autoimmune COVID - 19 Non - Opioid Pain • Abivertinib • CD38 DAR - T • CD38 ADC • CD47 mAb • PD - L1 mAb • Trop2 ADC • Bevacizumab ADNAB • Abivertinib • COVISTIX 1 • COVITRACK • COVI - AMG • COVIDROPS • COVISHIELD • Abivertinib • COVI -

  6. Slide 6: Platforms to Innovative Products

    Transforming Platforms to Saving Life Ρ Medicines Platforms to Innovative Products G - MAB • PD - L1 mAb • CD - 47 mAb • Anti - COVID nAbs COVISHIELD nAbs • ROR1 • Sofusa Lymphatic Delivery o TNF, PD1, CTLA4 • CD38 ADC • BCMA ADC • Trop2 ADC • VEGF ADNAB • CD20 ADNAB • PD - L1 ADNAB • CD38 DAR - T •

  7. Slide 7: Cancer Programs

    Cancer Programs 7 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  8. Slide 8: Cancer Pipeline

    Cancer Pipeline © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 8 Key Programs Indication Preclinical FDA Approved Abivertinib NSCLC Abivertinib B Cell Lymphomas PD-L1* SCLC * In China PD-L1* Cervical Cancer * In China CD47 Solid Tumors CD38 DAR-T Multiple Myeloma CD38 ADC Amyloidosis and Mul

  9. Slide 9: Abivertinib (STI-5656): NSCLC and B Cell Lymphomas

    9 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved ABIVERTINIB (STI - 5656): NSCLC and B Cell Lymphomas • Abivertinib maleate (STI - 5656) is a small molecule third - generation tyrosine kinase inhibitor (TKI) for both mutant epidermal growth factor receptor (EGFR) and Bruton tyrosine kinase (

  10. Slide 10: Abivertinib Efficacy in EGFR T790M+ NSCLC Patients

    Abivertinib Efficacy in EGFR T790M + NSCLC Patients (Interim Data Analyses Presented at ASCO 2019) © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 10 Among 209 response evaluable patients, per investigator assessment: 93.3% (n/N: 195/209) subjects achieved tumor shrinkage at target lesions 68

  11. Slide 11: COVID Programs

    COVID - 19 Programs 11 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  12. Slide 12: COVID Portfolio

    COVID - 19 Portfolio © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 12 Key Programs Indication Preclinical FDA Approved COVISTIX™ (diagnostic) Antigen Test Emergency Use Authorization (EUA) Approval by COFEPRIS in Mexico and cleared for commercialization COVIDROPS™ (treatment) Neutralizing A

  13. Slide 13: Largest Pipeline of Innovative COVID Solutions

    13 Largest Pipeline of Innovative COVID - 19 Solutions PREVENT DETECT TREAT MultiValent mRNA Vaccine COVISTIX Ρ COVITRACK Ρ SARS - CoV - 2 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved COVIDROPS Ρ COVI - AMG Ρ Antivirals RESCUE Abivertinib Ρ COVI - MSC Ρ Potent neutralizing antibodies for o

  14. Slide 14: Detect Early – Treat Timely

    14 DETECT EARLY – TREAT TIMELY © 202 1 Sorrento Therapeutics, Inc. All Rights Reserved … to save lives Abivertinib (STI - 5656) “When given early, neutralizing antibodies given IV have shown a > 70% reduction in hospitalizations” 1 CDC, July 23, 2021 COVID cases are on the rise now in 90% of US juri

  15. Slide 15: Diagnostics

    Diagnostics 15 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  16. Slide 16: COVISTIX Sensitive and Simple Virus Antigen Test

    • Simple: Eliminates laborious extraction step and is designed for potential point - of - care (moderately trained technicians) or at - home use • Accurate: Rapid and highly sensitive platinum colloid - based lateral flow immunoassay to detect SARS - CoV - 2 virus antigens • Rapid: Produces results

  17. Slide 17: Therapeutics

    Therapeutics 17 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  18. Slide 18: COVI-AMG (STI-2020)

    COVI - AMG Ρ (STI - 2020)* 18 • COVI - AMG: i) Phase 1 clinical trial completed in healthy normal individuals demonstrating good safety and pharmacokinetics profile and ii) planned Phase 2 systemic treatment in combination with COVIDROPS in an outpatient setting • COVI - AMG potently neutralizes the

  19. Slide 19: COVIDROPS (STI-2099)

    COVIDROPS Ρ (STI - 2099)* 19 • COVIDROPS is an intranasal formulation of the highly potent neutralizing antibody STI - 2020 (COVI - AMG) • COVIDROPS: completed a Phase 1 safety and pharmacokinetic study in healthy volunteers and a Phase 2 study in outpatients with mild COVID - 19 disease is in proce

  20. Slide 20: COVISHIELD Antibody STI-9167 Neutralizes Multiple Variants

    COVISHIELD Antibody: STI - 9167 Potently Neutralizes Multiple SARS - CoV - 2 Variants 20 • STI - 9167 developed at Sorrento in collaboration with scientists at the Mt. Sinai Center for Therapeutic Antibody Development • STI - 9167 displays potent in vivo neutralization of SARS - CoV - 2 and Variants

  21. Slide 21: Vaccines

    Vaccines 21 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  22. Slide 22: STI SARS-CoV-2 Spike RBD Protein Subunit Vaccine

    STI SARS - CoV - 2 Spike RBD Protein Subunit Vaccine Potential Advantages of using RBD for vaccination: • Strong protection against challenge by Delta VoC • Exposure of key neutralizing epitopes on the RBD to the immune system that are hidden in the closed whole spike protein conformation • Efficien

  23. Slide 23: MultiValent mRNA SARS-CoV-2 Vaccine

    23 MultiValent mRNA SARS - CoV - 2 Vaccine © 2021 Sorrento Therapeutics, Inc. All Rights Reserved • Sorrento has developed a MultiValent SARS - CoV - 2 vaccine strategy to address the current global public health demand • Potential for hundreds of millions of vaccine doses to be delivered to underse

  24. Slide 24: Antivirals

    Antivirals 24 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  25. Slide 25: MPI inhibits SARS-CoV-2 Replication by Targeting Protease Mpro

    MPI - 8 inhibits SARS - CoV - 2 Replication by Targeting the Virus Protease M pro © 2021 Sorrento Therapeutics, Inc. All Rights Reserved • Sorrento is engineering small molecule Coronavirus protease inhibitors originally discovered at Texas A&M University for optimal safety, antiviral efficacy, and

  26. Slide 26: Rescue Treatments

    Rescue Treatments 26 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  27. Slide 27: Abivertinib (STI-5656) for COVID-19 Respiratory Failure

    27 • STI - 5656 is an oral treatment (100 mg daily) and has completed 2 Phase 2 clinical studies as a treatment of severe COVID - 19 symptoms (ARDS) in US (96) and Brazil (400). • STI - 5656 has been shown to be safe and well tolerated at doses up to 600 mg daily in the treatment of non - small cell

  28. Slide 28: COVI-MSC (STI-8282) for Patients with Acute Lung Damage

    28 • COVI - MSC (STI - 8282): Allogeneic culture - expanded adipose - derived Mesenchymal stromal cells for the rescue of patients with lung damage and acute respiratory distress syndrome (ARDS) due to COVID - 19 • Preclinical studies have demonstrated that COVI - MSCs may produce a reduction in lun

  29. Slide 29: Non-Opioid Pain Management Programs

    Non - Opioid Pain Management Programs 29 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved

  30. Slide 30: Non-Opioid Pain Therapeutics

    Non - Opioid Pain Therapeutics © 2021 Sorrento Therapeutics, Inc. All Rights Reserved 30 Key Programs Indication Preclinical FDA Approved ZTlido™ 1.8% Postherpetic Neuralgia - PHN SP-102 Lumbar Radicular/Sciatica Pain SP-103 Acute Back Pain SP-104 Fibromyalgia RTX (resiniferatoxin) – Epidural Intrac

  31. Slide 31: Marketed Product: ZTlido 1.8%

    US FDA APPROVAL – FEBRUARY 2018 COMMERCIAL LAUNCH – OCTOBER 2018 Marketed Product: ZTlido® 1.8% (FDA approved for relief of pain associated with PHN ) Lidocaine Patch Market Overview >3 .5 million prescriptions per year More than 129 million prescription lidocaine patches were sold in the US in 2020

  32. Slide 32: Developing SP-102 as a non-opioid injectable for low back pain

    Developing SP - 102 as a non - opioid injectable therapeutic for low back pain Novel viscous gel formulation, optimized for epidural injection Novel biocompati ble excipient enables extended local effect On track to be the first and only FDA - approved epidural steroid product Currently used product

  33. Slide 33: SP-102 – On Track to be the First Steroid Formulation With FDA-Approved Label

    Well - tolerated. Key viscous excipient, long history of use including safety and safer repeat injections ᤯ ᤯ Fast acting onset of effect with less spread ᤯ Potent non - particulate steroid (injectable dexamethasone sodium phosphate viscous gel) ᤯ Pre - filled syringe for epidural use ᤯ Gel formulat

  34. Slide 34: SP-103 Next-Generation, ZTlido 5.4%

    • Triple strength dose of lidocaine • S uperior adhesion and efficient formulation • Expect to initiate Phase 2 trial in 2 H 2021 • For the treatment of low back pain – a substantially larger opportunity than PHN 34 • Innovative technology delivering equivalent therapeutic dose to current lidocaine

  35. Slide 35: Resiniferatoxin (RTX)

    Resiniferatoxin (RTX) 35 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved Resiniferatoxin is a potent agonist of the transient receptor potential cation channel sub - family V member 1 (TRPV 1 ) predominantly found in a subpopulation of small C and A delta sensory neurons most often involved i

  36. Slide 36: RTX Clinical Studies

    RTX Clinical Studies OA KNEE PAIN Phase 1b double - blinded, placebo - controlled study to assess the safety and preliminary efficacy of intra - articular administration of Resiniferatoxin or saline control (as placebo group) for the treatment of moderate to severe pain due to osteoarthritis of the

  37. Slide 37: Executive Team

    Executive Team sorrento [a ta Shawn Sahebi, Pho. Brian Cooley Bill Farley ‘Alexis Nahama, DVM. Brian Sun

Sorrento Therapeutics — Investor Presentation (September 2021) on 6ix